Settlement Funding on Pharmaceutical Lawsuits

Check Eligibility by State: State Eligibility Directory

“I was very pleased at the professional manner with which my funding was handled as well as the quick reply and wiring of funds. On a scale of 1 to 10, a definite 10…..” Pharmaceutical Litigation Funding
Pharmaceutical Litigation

How lawsuit funding can help

Class action pharmaceutical litigation over the last several decades paints a bleak testimony to the utter lack of integrity and responsibility that drives many large pharmaceuticals today. Ethical responsibility and moral integrity in many companies has given way to financial expediency and consumers worldwide continue to pay an enormous price for that trade-off.

TriMark Legal Funding LLC offers non-recourse pre settlement funding and post settlement funding in amounts from $1,000 up to $100,000 (depending on the type of case) on a wide variety of pharmaceutical lawsuits including:

Pharmaceutical Lawsuits

For big pharma, it’s all about the money

Pharmaceutical lawsuits fall under the broader category of product liability. Millions of product liability lawsuits have been filed against big pharmaceutical companies over the last several decades and unfortunately, there is no indication that it’s slowing down. In fact, it seems to be gaining momentum.

In the race to get new, highly profitable drugs and medical devices to a worldwide market quickly, many pharmaceuticals cut corners and take shortcuts. They conceal, misrepresent, spin or simply suppress critical test data that could prevent injury to the public. Instead of investing the money to create better, safer products, a growing trend has been to simply build billions of dollars into their budgets in anticipation of inevitable future litigation and then sell the dangerous drugs or defective medical devices like crazy until the truth comes out and the music finally stops.

the real bottom line: putting profits before people

In a chilling precursor of things to come, the most egregious example to date of this despicable practice is Merck & Co. – the manufacturer of Vioxx, a prescription pain reliever. Merck is the poster-child for unchecked pharmaceutical greed and irresponsibility because it possessed clear evidence from it’s own internal studies – prior to ever even receiving FDA approval – that Vioxx increased the risk of heart attack and other serious cardiac events by nearly 700%.

Pharmaceutical Lawsuits

Instead of acting responsibly, doing the right thing or protecting the public by withdrawing Vioxx, Merck suppressed the data, sought and received FDA approval and took it to market anyway and instructed its sales reps to market it very aggressively knowing that soon enough, the party would be over.

And over it was; amid tens of thousands of deaths and a firestorm of litigation, Merck finally withdrew the product in 2004 – but not before they had reaped tens of billions of dollars in profit over a span of six years.

Merck viewed the 160,000+ heart attacks and strokes and nearly 30,000 deaths it had caused as “unfortunate” – and the $4.85 billion settlement (only a tiny fraction of Vioxx’ overall profit) as merely “the cost of doing business”.

Was the Vioxx debacle the deterrent everyone hoped it would be? Not at all; Merck has other products currently involved in class action litigation and they’re not alone. Pfizer, Wyeth, GlaxoSmithKline, Forest Laboratories, Bayer AG, Johnson & Johnson, Eli Lilly and Hoffman-LaRoche are but a few of the companies that have joined this trend and are currently involved in massive class action litigation.

Pharmaceutical lawsuit loans are Fast, discreet and Affordable

Pharmaceutical Lawsuit Loans

TriMark Legal Funding LLC provides fast, affordable litigation funding on a number of different types of dangerous drug and defective medical devices nationwide. Lawsuit advances are 100% risk-free because you only repay the advance if you win your case; if your case is lost, you owe nothing. Call us at 1-877-WECANBUY if you have questions or if you need money fast, apply now.